RecruitingNot ApplicableNCT07707258

Remimazolam Combined With Oliceridine for Sedation in Elderly Patients Undergoing Gastrointestinal Endoscopy

Hemodynamic and Oxygenation Profiles of Remimazolam Combined With Oliceridine Versus Sufentanil in Elderly Patients Undergoing Painless Gastrointestinal Endoscopy: A Randomized, Double-blind, Controlled Trial

Sponsor

Baoshan Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Enrollment

240 participants

Start Date

Jul 17, 2026

Study Type

INTERVENTIONAL

Conditions

Sedation Gastrointestinal Endoscopy

Summary

This study aims to evaluate the sedative efficacy and safety of remimazolam combined with oliceridine in elderly patients undergoing painless gastrointestinal endoscopy. Elderly patients often face higher risks of respiratory and hemodynamic depression during clinical sedation. This trial will investigate whether the combination of remimazolam and oliceridine can provide stable sedation, maintain stable vital signs, and reduce the incidence of adverse events such as hypoxemia and postoperative cognitive fluctuation in this vulnerable population.

Eligibility

Min Age: 65 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Oliceridine Fumarate and a drug called Remimazolam Tosilate for Injection for people with gastrointestinal endoscopy and sedation. The study is currently recruiting participants at 1 location. People eligible for this study include aged 65 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRemimazolam Tosilate for Injection

Administered intravenously for sedation induction and maintenance during gastrointestinal endoscopy. The dosage will be titrated according to the patient's sedation depth and clinical response.

DRUGOliceridine Fumarate

Administered intravenously before or during the procedure to provide stable analgesic cooperation and optimize procedural sedation quality in elderly patients.